KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Halozyme Therapeutics (HALO) over the last 16 years, with Q4 2025 value amounting to -$741.8 million.

  • Halozyme Therapeutics' Cash from Investing Activities fell 261624.15% to -$741.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$545.8 million, marking a year-over-year decrease of 10775.23%. This contributed to the annual value of -$545.8 million for FY2025, which is 10775.23% down from last year.
  • As of Q4 2025, Halozyme Therapeutics' Cash from Investing Activities stood at -$741.8 million, which was down 261624.15% from $201.6 million recorded in Q3 2025.
  • Over the past 5 years, Halozyme Therapeutics' Cash from Investing Activities peaked at $201.6 million during Q3 2025, and registered a low of -$741.8 million during Q4 2025.
  • Moreover, its 5-year median value for Cash from Investing Activities was -$44.9 million (2021), whereas its average is -$89.9 million.
  • In the last 5 years, Halozyme Therapeutics' Cash from Investing Activities crashed by 817876.98% in 2023 and then soared by 45556.63% in 2024.
  • Halozyme Therapeutics' Cash from Investing Activities (Quarter) stood at -$299.5 million in 2021, then surged by 99.42% to -$1.7 million in 2022, then tumbled by 374.86% to -$8.3 million in 2023, then skyrocketed by 455.57% to $29.5 million in 2024, then crashed by 2616.24% to -$741.8 million in 2025.
  • Its Cash from Investing Activities stands at -$741.8 million for Q4 2025, versus $201.6 million for Q3 2025 and $84.8 million for Q2 2025.